Apremilast for treatment of recurrent erythema multiforme.
Dermatol Online J
; 23(1)2017 Jan 15.
Article
em En
| MEDLINE
| ID: mdl-28329479
ABSTRACT
Recurrent erythema multiforme with oralinvolvement is therapeutically challenging.Apremilast has been used with success in resolvingthe oral aphthae of Behçet disease, prompting theuse of the drug in patients with oral erosions fromerythema multiforme. Three patients with oralerythema multiforme were given apremilast at dosesof 30-60mg daily. Complete clearance of the lesionswere observed in all three patients, including thoserefractory to other standard therapies. Apremilast maypresent an effective option for recurrent erythemamultiforme for patients who have failed trials antiviraland immunosuppressive therapies.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Talidomida
/
Anti-Inflamatórios não Esteroides
/
Eritema Multiforme
/
Doenças da Boca
Limite:
Adult
/
Child
/
Female
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article